RU2018123524A - Фармацевтическая диагностика - Google Patents

Фармацевтическая диагностика Download PDF

Info

Publication number
RU2018123524A
RU2018123524A RU2018123524A RU2018123524A RU2018123524A RU 2018123524 A RU2018123524 A RU 2018123524A RU 2018123524 A RU2018123524 A RU 2018123524A RU 2018123524 A RU2018123524 A RU 2018123524A RU 2018123524 A RU2018123524 A RU 2018123524A
Authority
RU
Russia
Prior art keywords
patient
pyridin
amide
pi3k inhibitor
cancer
Prior art date
Application number
RU2018123524A
Other languages
English (en)
Russian (ru)
Other versions
RU2018123524A3 (enExample
Inventor
Эмманюэлль ДИ ТОМАЗО
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2018123524A publication Critical patent/RU2018123524A/ru
Publication of RU2018123524A3 publication Critical patent/RU2018123524A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2018123524A 2015-12-03 2016-11-30 Фармацевтическая диагностика RU2018123524A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262620P 2015-12-03 2015-12-03
US62/262,620 2015-12-03
PCT/IB2016/057208 WO2017093905A1 (en) 2015-12-03 2016-11-30 Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna

Publications (2)

Publication Number Publication Date
RU2018123524A true RU2018123524A (ru) 2020-01-09
RU2018123524A3 RU2018123524A3 (enExample) 2020-04-02

Family

ID=57517943

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018123524A RU2018123524A (ru) 2015-12-03 2016-11-30 Фармацевтическая диагностика

Country Status (13)

Country Link
US (2) US20180353515A1 (enExample)
EP (1) EP3383391A1 (enExample)
JP (1) JP2018535997A (enExample)
KR (1) KR20180084830A (enExample)
CN (1) CN108366998A (enExample)
AU (1) AU2016362683B2 (enExample)
CA (1) CA3006419A1 (enExample)
HK (1) HK1253737A1 (enExample)
IL (1) IL259716A (enExample)
MX (1) MX2018006777A (enExample)
RU (1) RU2018123524A (enExample)
TW (1) TW201722429A (enExample)
WO (1) WO2017093905A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081549A1 (en) * 2018-10-15 2020-04-23 The Regents Of The University Of California Methods and materials for assessing and treating cancer
CN116240287A (zh) * 2023-01-17 2023-06-09 普洱市人民医院 基于循环肿瘤dna的乳腺癌标志物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048627B2 (en) 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20130317037A1 (en) * 2010-11-16 2013-11-28 Glaxosmithkline Intellectual Property Development Limited Method of administration and treatment
EP2830621B1 (en) * 2012-03-29 2020-10-21 Novartis AG Pharmaceutical diagnostic
EP3140427B1 (en) * 2014-05-09 2020-10-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Also Published As

Publication number Publication date
RU2018123524A3 (enExample) 2020-04-02
HK1253737A1 (zh) 2019-06-28
TW201722429A (zh) 2017-07-01
MX2018006777A (es) 2018-08-01
AU2016362683B2 (en) 2019-11-07
US20200138824A1 (en) 2020-05-07
US20180353515A1 (en) 2018-12-13
KR20180084830A (ko) 2018-07-25
CN108366998A (zh) 2018-08-03
WO2017093905A1 (en) 2017-06-08
CA3006419A1 (en) 2017-06-08
AU2016362683A1 (en) 2018-05-31
IL259716A (en) 2018-07-31
EP3383391A1 (en) 2018-10-10
JP2018535997A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
Rogers et al. Esophageal cancer: emerging therapeutics
EP4326270A1 (en) Diagnostic and treatment of cancer using c-met inhibitor
US20210355545A1 (en) Methods and materials for assessing and treating cancer
JP2019524768A5 (enExample)
AR065911A1 (es) Beta - klotho
AU2013326463A1 (en) Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
JP2017513908A5 (enExample)
Shen et al. LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer
US20150361504A1 (en) Biomarker for predicting response of cll to treatment with a btk inhibitor
US20180298447A1 (en) Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation
JP2014513097A5 (enExample)
Bohn et al. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation
JP2025511940A5 (enExample)
Nelhűbel et al. EGFR alterations influence the cetuximab treatment response and c-MET tyrosine-kinase inhibitor sensitivity in experimental head and neck squamous cell carcinomas
Laru The effects of surgical and medical treatments on the prognosis of synchronous metastatic renal cell cancer
Jeong et al. Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
KR102241063B1 (ko) 예측성 바이오마커에 대한 검정법
Guo et al. Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy
JP2018535997A5 (enExample)
Calabria et al. The new challenge in oncology: Next-generation sequencing and its application in precision medicine
JP2023542273A (ja) Amlを処置するための治療、ならびにraraアゴニスト、低メチル化剤、およびbcl-2阻害剤の使用
Bambury et al. Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors
Baek et al. Prediction of late breast cancer-specific mortality in recurrence-free breast cancer survivors treated for five years with tamoxifen
Rajkhowa et al. From genes to recovery: precision medicine and its influence on multidrug resistant breast cancer
Kim et al. Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20211122